A DNA aptamer nanostructure enables targeted doxorubicin delivery to AML cells, improving treatment efficacy and safety, ...
Kura Oncology and Kyowa Kirin announced that clinical data from the KOMET-007 trial, evaluating ziftomenib in combination with the standard chemotherapy regimen of cytarabine and daunorubicin (7+3) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback